AGM Chair and CEO Presentation

For personal use only

ASX Announcement

11 November 2021

AGM Chair's Address and CEO's presentation

AnteoTech Ltd (ASX: ADO) ("AnteoTech" or "the Company") is pleased to provide a copy of the Chairman's address together with the CEO's presentation to the Annual General Meeting (AGM) of AnteoTech, to be held at 1pm (Brisbane time) today.

The AGM will be held online. Shareholders and proxyholders will be able to listen, view presentations, vote and ask questions during the meeting in real-time through the Lumi virtual platform, for which details are available via https://www.anteotech.com/investors/2021agm/

This announcement has been authorised for release by the Board.

For more information, please contact:

Friederike Graser, Communications Manager, AnteoTech Ltd: +61 (0) 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

About AnteoTech - (ASX:ADO)

AnteoTech is a surface chemistry company with Intellectual Property ("IP") in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company's purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.

AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on Twitter (@AnteoTech_), LinkedIn.

Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive Lates News bulletin, our email alert service.

For personal use only

our presence in Europe and South East Asia, we expect to enter the US market in 2022, on the back of the Multiplex COVID/ Flu test and work on the market entry plan is well underway.

My comments have focused on our accelerated strategy of moving up the value chain to be an assay developer in our own right, but I should not overlook the validation of AnteoBind through our raw material sales. We were pleased to see the success of our local customer Ellume in achieving FDA accreditation in December and the subsequent success in securing a major US Department of Defence contract, which was also a validation of AnteoBind in the world's largest single market for Point of Care testing. The Serum Institute of India, the world's largest vaccine manufacturer, has also grown to become a major customer of AnteoBind applying it in the quality control processes involved in vaccine production. We also achieved our first sales of services in assisting clients in solving difficult assay challenges with the link of both capability recognition and pulling through AnteoBind for future sales.

The addressable market for our Life Science business has been rapidly growing with previous predictions of US$ 11.5 B by 20262 now being seen as low, with the rapid uptake of Point of Care testing driven by the pandemic. The rapid testing market for COVID, whilst very competitive, is still strong and increasing globally.

Whilst the spotlight may have been on Life Science this past year, Manuel Wieser, our Head of Energy and his small but highly capable team have also been making strong progress. As flagged in my address last year, we have been focused on building interest around AnteoX, our cross-linking additive. We have had AnteoX in evaluation with several collaborators to both raise the profile of AnteoX and AnteoTech but more importantly gather market intelligence on how it best fits and can be modified to better position it into the market needs of battery manufacturers and suppliers. Collaborator 8, a large multi-national North Asia Speciality Chemical company verified the electrochemical uplift that AnteoX, as a binder component, provides in high silicon content anode designs, reporting a performance gain in line with our internal results which showed an uplift between 15-26%. Collaborator 8 and AnteoTech jointly showcased these results to one of their customers, a high-performance battery developer and manufacturer. Following the presentation, the customer, has not only expressed interest in AnteoX but also in the high silicon content anode concept design developed in-house during AnteoX testing. Evaluation of AnteoX using our reference design is now in progress with this customer, with results anticipated early in the New Year, which will inform the next steps in the commercialisation of AnteoX.

In parallel, Collaborator 2, a major European silicon manufacturer has progressed discussions and introductions to their customer network which includes automotive producers giving the opportunity for Manuel to showcase the results the team had generated using Collaborator 2's micro silicon and AnteoX in an in-house designed silicon dominant electrode.

The progress with both these Collaborators, along with the encouragement and guidance from our newly formed Energy Advisory Board are giving us confidence that the Energy team is on the right track to commercialise AnteoX.

Our Energy activities remain focused to meet a significant and growing market. The latest International Energy Agency World Energy Outlook 2021 which has just been released, is forecasting the lithium-ion battery market to hit US$ 130 Billion pa under current policy settings and with the adoption of net zero policy settings hit US$ 470 Billion pa by 2030 and expanding to US$ 860 Billion pa by 2050. The IEA report states that "Batteries will play a central part of the new energy economy." AnteoTech's Energy development path is feeding directly into this coming wave of change.

Both divisions are positioned to see the continued acceleration of the transformation journey AnteoTech embarked on when embracing the current strategy back in 2018 to focus our development and commercial efforts where our IP makes a difference and a positive contribution to meeting the needs of these global winds of change.

For personal use only

We have strengthened our board through the year with the addition of Ms Glenda McLoughlin and Dr. Katherine Woodthorpe, and we look forward to their contribution to the journey ahead. In addition, we were pleased to announce the establishment of our two new advisory boards, with Professor Paul Young and Professor Dominic Dwyer joining the Clinical Board and Mr. Oliver Gross and Dr. Kevin Eberman joining the Energy Board. These external eminent experts in their respective fields have already started to bring strong guidance to the Board and management as we chart our future pathway in the Life Science and Energy businesses.

On behalf of the Board, we extend our appreciation to our shareholders, both long standing and new for your ongoing interest and commitment to the company. The capital raising in April/ May which combined raised $ 20 million, far exceeded our expectations. The funds are being deployed to build our capability, establish our own manufacturing facility in Brisbane and support the rollout of the EuGeni platform.

I extend my thanks to our CEO Derek Thomson, and to all our staff who have delivered the AnteoTech transformation journey to date and have not slowed the pace one iota over the past two challenging but exciting years and are focused on continuing to drive the company forward for our shareholders.

Finally, my thanks to my board colleagues for their focus and commitment over the past year, including Matt Sanderson who stepped off the board back in April but was a foundation member of the board that set the strategy in place to bring the company to where it is today. A special thank you to both Chris Parker and Geoff Cumming who have supported Derek and the Life Science team well beyond the expectations of the role of a non-executive director in accelerating the path for our EuGeni platform and our first commercial rapid antigen test. Having such commercial and technical expertise in our Life Science field, now complemented with the addition of Glenda and Katherine at Board level, gives AnteoTech the ability to leverage our capability and deliver to our potential on the international stage.

All at AnteoTech are committed and focused on driving the company forward to commercial success and to the rewards that success will bring all shareholders.

I will now turn to the formal business of the meeting.